High Wnt Signaling Represses the Proapoptotic Proteoglycan syndecan-2 in Osteosarcoma Cells
- 30 June 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (13) , 5399-5408
Abstract
Osteosarcoma is characterized by frequent relapse and metastatic disease associated with resistance to chemotherapy. We previously showed that syndecan-2 is a mediator of the antioncogenic effect of chemotherapeutic drugs. The purpose of this work was to elucidate molecular mechanisms responsible for the low expression of syndecan-2 in osteosarcoma. We compared the regulatory activity of cis-acting DNA sequences of the syndecan-2 gene in osteosarcoma and osteoblastic cell lines. We identified a DNA region that negatively regulates syndecan-2 transcription in the osteosarcoma cells. T-cell factors (TCF) bind to this sequence in vivo. Wnt3a stimulation, β-catenin activation, and TCF overexpression resulted in syndecan-2 repression, whereas Wnt inhibition using sFRP-1 increased syndecan-2 expression in U2OS cells. RhoA activation blunted the stimulatory effect of sFRP-1 on syndecan-2 transcription, whereas RhoA inhibition enhanced syndecan-2 expression. These results indicate that Wnt/β-catenin and Wnt/RhoA signaling contribute to syndecan-2 repression. The alteration of syndecan-2 expression in osteosarcoma cell lines also seemed to be related to a higher shedding, controlled by Wnt/RhoA. Conversely, syndecan-2 was found to activate its own expression in U2OS cells through RhoA inhibition. These data identify a molecular network that may contribute to the low expression of the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. The high activity of the canonical Wnt pathway in the different osteosarcoma cells induces a constitutive repression of syndecan-2 transcription, whereas Wnt/RhoA signaling blocks the amplification loop of syndecan-2 expression. Our results identify syndecan-2 as a Wnt target and bring new insights into a possible pathologic role of Wnt signaling in osteosarcoma. Cancer Res; 70(13); 5399–408. ©2010 AACR.Keywords
This publication has 37 references indexed in Scilit:
- Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in miceJournal of Clinical Investigation, 2009
- Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell InvasionJournal of Biological Chemistry, 2008
- Dominant Negative LRP5 Decreases Tumorigenicity and Metastasis of Osteosarcoma in an Animal ModelClinical Orthopaedics and Related Research, 2008
- Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathwayJournal of Clinical Investigation, 2007
- Syndecans in wound healing, inflammation and vascular biologyThe International Journal of Biochemistry & Cell Biology, 2007
- Syndecan-2 Is Expressed in the Microvasculature of Gliomas and Regulates Angiogenic Processes in Microvascular Endothelial CellsJournal of Biological Chemistry, 2006
- Syndecan-2The International Journal of Biochemistry & Cell Biology, 2006
- The Integrin-linked Kinase Regulates Cell Morphology and Motility in a Rho-associated Kinase-dependent MannerJournal of Biological Chemistry, 2004
- Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcomaInternational Journal of Cancer, 2002
- Breast Cancer Cells Release Factors That Induce Apoptosis in Human Bone Marrow Stromal CellsJournal of Bone and Mineral Research, 2001